T1	Disorder 104 121	adrenal carcinoma
N1 	Reference T1 UMLS:C0206686	adrenal carcinoma
T2	Pharmacological_substance 135 193	2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane
N1000 	Reference T2 MeSH:D008939	2,2-bis (2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane
T3	Disorder 263 277	hypoadrenalism
N2 	Reference T3 UMLS:C0001623	hypoadrenalism
T4	Disorder 359 373	hypoadrenalism
N3 	Reference T4 UMLS:C0001623	hypoadrenalism
T5	Pharmacological_substance 401 408	steroid
N1001 	Reference T5 MeSH:D013256	steroid
T6	Pharmacological_substance 430 443	Dexamethasone
N1002 	Reference T6 MeSH:D003907	Dexamethasone
T7	Pharmacological_substance 590 603	dexamethasone
N1003 	Reference T7 MeSH:D003907	dexamethasone
T9	Pharmacological_substance 929 937	o,p'-DDD
N1004 	Reference T9 MeSH:D008939	o,p'-DDD
T10	Disorder 952 966	hypoadrenalism
N4 	Reference T10 UMLS:C0001623	hypoadrenalism
T11	Pharmacological_substance 1057 1071	corticosteroid
N1005 	Reference T11 MeSH:D000305	corticosteroid
T8	Pharmacological_substance 23 31	o,p'-DDD
N1006 	Reference T8 MeSH:D008939	o,p'-DDD
T13	Pharmacological_substance 195 203	o,p'-DDD
N1007 	Reference T13 MeSH:D008939	o,p'-DDD
T16	Subject 86 98	Two patients
T17	Subject 239 252	Both patients
T19	Speculation_cue 938 944	may be
T20	Pharmacological_substance 320 333	dexamethasone
N1008 	Reference T20 MeSH:D003907	dexamethasone
T21	Pharmacological_substance 287 295	o,p'-DDD
N1009 	Reference T21 MeSH:D008939	o,p'-DDD
T23	Pharmacological_substance 525 533	o,p'-DDD
N1010 	Reference T23 MeSH:D008939	o,p'-DDD
T25	Pharmacological_substance 35 50	adrenal steroid
T29	Subject 760 778	these two patients
T34	Pharmacological_substance 1015 1022	steroid
N1011 	Reference T34 MeSH:D013256	steroid
T35	Speculation_cue 971 974	may
T37	Pharmacological_substance 677 684	steroid
N1012 	Reference T37 MeSH:D013256	steroid
T40	Combination 296 299	and
